This Article Figures Only Full Text Full Text (PDF) Correspondence: Submit a response Alert me when this article is cited Alert me when Correspondence are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Farlow, M. R. Search for Related Content PubMed Articles by Farlow, M. R.

NEUROLOGY 1997;48:30S-34S
© 1997 American Academy of Neurology

Alzheimer's disease: Clinical implications of the apolipoprotein E genotype

Martin R. Farlow, MD

From the Department of Neurology, Indiana University School of Medicine, Indianapolis, IN.
Address correspondence and reprint requests to Dr. Martin R. Farlow, Indiana University Medical Center, Department of Neurology, 541 Clinical Drive, Suite 583, Indianapolis, IN 46202-5111.

Abstract.

Article abstract-Inheritance of the apolipoprotein E (APOE = gene; apoE = protein) epsilon 4 gene is associated with a higher risk for development of Alzheimer's disease (AD) and for occurrence of this illness at a younger age. APOE gene dose and genotype interact with gender, ethnicity, and age to influence the probability of developing AD, as well as the rate of disease progression. The sensitivity and specificity of APOE genotyping, however, and the longer-term implications of the epsilon 4 allele as a susceptibility factor for AD, are not yet adequately understood to recommend the use of APOE genotyping in genetic counseling of asymptomatic family members of AD patients. Insufficient evidence also exists at this time to recommend APOE genotyping as an adjuvant for the differential diagnosis of dementia or as a possible predictor for response to drug therapy. These potential future clinical indications for apoE genotyping are under active investigation.

NEUROLOGY 1997;48(Suppl 6): S30-S34